Zobrazeno 1 - 10
of 217
pro vyhledávání: '"Giovanni, Sparacino"'
Autor:
Alessandro Guazzo, Enrico Longato, Gian Paolo Fadini, Mario Luca Morieri, Giovanni Sparacino, Barbara Di Camillo
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-10 (2023)
Abstract Writing notes is the most widespread method to report clinical events. Therefore, most of the information about the disease history of a patient remains locked behind free-form text. Natural language processing (NLP) provides a solution to a
Externí odkaz:
https://doaj.org/article/e8d3c355070848f7955de2c1147f3064
Autor:
Francesco Prendin, Jacopo Pavan, Giacomo Cappon, Simone Del Favero, Giovanni Sparacino, Andrea Facchinetti
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-13 (2023)
Abstract Machine learning has become a popular tool for learning models of complex dynamics from biomedical data. In Type 1 Diabetes (T1D) management, these models are increasingly been integrated in decision support systems (DSS) to forecast glucose
Externí odkaz:
https://doaj.org/article/08cf8f36b4354d57bd6f49e44f4f068c
Autor:
Nunzio Camerlingo, Ilaria Siviero, Martina Vettoretti, Giovanni Sparacino, Simone Del Favero, Andrea Facchinetti
Publikováno v:
Frontiers in Bioengineering and Biotechnology, Vol 11 (2023)
Introduction: The retrospective analysis of continuous glucose monitoring (CGM) timeseries can be hampered by colored and non-stationary measurement noise. Here, we introduce a Bayesian denoising (BD) algorithm to address both autocorrelation of meas
Externí odkaz:
https://doaj.org/article/81af30b11a294800badbef9b8928535d
Autor:
Mario Luca Morieri, Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Angelo Avogaro, Gian Paolo Fadini
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-12 (2022)
Abstract Background Results of cardiovascular outcome trials enabled a shift from “treat-to-target” to “treat-to-benefit” paradigm in the management of type 2 diabetes (T2D). However, studies validating such approach are limited. Here, we exa
Externí odkaz:
https://doaj.org/article/4665cef88de54d929229a261dbca2340
Publikováno v:
Cardiovascular Diabetology, Vol 21, Iss 1, Pp 1-11 (2022)
Abstract Aim Treatment algorithms define lines of glucose lowering medications (GLM) for the management of type 2 diabetes (T2D), but whether therapeutic trajectories are associated with major adverse cardiovascular events (MACE) is unclear. We explo
Externí odkaz:
https://doaj.org/article/50568d8111f147cfb48bb4c9655d3dae
Autor:
Alessandro Guazzo, Enrico Longato, Mario Luca Morieri, Giovanni Sparacino, Bruno Franco-Novelletto, Maurizio Cancian, Massimo Fusello, Lara Tramontan, Alessandro Battaggia, Angelo Avogaro, Gian Paolo Fadini, Barbara Di Camillo
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-11 (2022)
Abstract Predicting the risk of cardiovascular complications, in particular heart failure hospitalisation (HHF), can improve the management of type 2 diabetes (T2D). Most predictive models proposed so far rely on clinical data not available at the hi
Externí odkaz:
https://doaj.org/article/1c8a53bef208449a9bb23ea74d0375c8
Autor:
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini
Publikováno v:
Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-12 (2021)
Abstract Aim We aimed to compare cardiovascular outcomes of patients with type 2 diabetes (T2D) who initiated GLP-1 receptor agonists (GLP-1RA) or basal insulin (BI) under routine care. Methods We accessed the administrative claims database of the Ve
Externí odkaz:
https://doaj.org/article/447b44f87db0441db24a3ed1de63dab6
Autor:
Jill Carlton, Frans Pouwer, Alan Brennan, Stephanie A Amiel, Pratik Choudhary, Simon Heller, Bastiaan E de Galan, Jane Speight, Ulrik Pedersen-Bjergaard, Giovanni Sparacino, Helen Colhoun, Christel Hendrieckx, Rory McCrimmon, Stephanie Amiel, Mark Evans, Eric Renard, Mark Ibberson, Rory J McCrimmon, Sean Sullivan, Stephen Gough, Hannah Chatwin, Melanie Broadley, Uffe Søholm, Ohad Cohen, Søren E Skovlund, Cees Tack, Bastiaan de Galan, Thomas Pieber, Julia Mader, Bernard Thorens, Jakob Haardt, Zvonko Milicevic, Mahmood Kazemi, Sanjoy Dutta, Dominique Robert, Wendy Wolf
Publikováno v:
BMJ Open Diabetes Research & Care, Vol 10, Iss 4 (2022)
Introduction The aim of this study was to determine the psychometric properties of the 12-Item Hypoglycemia Impact Profile (HIP12), a brief measure of the impact of hypoglycemia on quality of life (QoL) among adults with type 1 (T1D) or type 2 diabet
Externí odkaz:
https://doaj.org/article/8065d6a74d4649e09328bccd4acc7a5b
Autor:
Enrico Longato, Barbara Di Camillo, Giovanni Sparacino, Lara Tramontan, Angelo Avogaro, Gian Paolo Fadini
Publikováno v:
Cardiovascular Diabetology, Vol 19, Iss 1, Pp 1-12 (2020)
Abstract Background Cardiovascular outcome trials in high-risk patients showed that some GLP-1 receptor agonists (GLP-1RA), but not dipeptidyl-peptidase-4 inhibitors (DPP-4i), can prevent cardiovascular events in type 2 diabetes (T2D). Since no trial
Externí odkaz:
https://doaj.org/article/c76f7e5a0ad54b6092e7c3c7c8f6108a
Autor:
Francesco Prendin, José-Luis Díez, Simone Del Favero, Giovanni Sparacino, Andrea Facchinetti, Jorge Bondia
Publikováno v:
Sensors, Vol 22, Iss 22, p 8682 (2022)
Accurate blood glucose (BG) forecasting is key in diabetes management, as it allows preventive actions to mitigate harmful hypoglycemic/hyperglycemic episodes. Considering the encouraging results obtained by seasonal stochastic models in proof-of-con
Externí odkaz:
https://doaj.org/article/5aa9b8c0c3ec4eadbfca21d202090801